Navigation Links
FDA Approves Product to Prevent Bleeding in People With Rare Genetic Defect
Date:2/17/2011

SILVER SPRING, Md., Feb. 17, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Corifact, the first product intended to prevent bleeding in people with the rare genetic defect congenital Factor XIII deficiency.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Patients with congenital Factor XIII deficiency don't make enough Factor XIII, a substance that circulates in the blood and is important for normal clotting. Without treatment, people with the condition are at risk for life-threatening bleeding.

Congenital Factor XIII deficiency is rare and affects 1 out of every 3 million to 5 million people in the United States. The deficiency may lead to soft tissue bruising, mucosal bleeding and fatal intracranial bleeding. Newborns with Factor XIII deficiency may have umbilical cord bleeding.

"This product helps fill an important need," said Karen Midthun, M.D., director of the FDA's Center for Biologics Evaluation and Research.

Corifact received orphan-drug designation by the FDA because it is intended for use in a rare disease or condition. It was approved for marketing under the FDA's accelerated approval regulations that require an on-going study to demonstrate that patients actually receive the clinical benefit predicted by the data obtained so far.

The FDA approved Corifact based on results of a clinical study of 14 people, including children, with congenital Factor XIII deficiency. The most common side effects observed were hypersensitivity reactions (allergy, rash, pruritus, and erythema), chills, fever, arthralgia, headache, elevated thrombin-antithrombin levels, and an increase in liver (hepatic) enzymes.

Corifact is made from the pooled plasma of healthy donors. People receiving Corifact may develop antibodies against Factor XIII that may make the product ineffective. It potentially can cause adverse
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves First 3-D Mammography Imaging System
2. FDA Approves 1st Pacemaker Designed to Work Safely During Some MRI Exams
3. FDA Approves Hologics Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical
4. FDA Approves Drug to Reduce Risk of Preterm Birth in At-Risk Pregnant Women
5. FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth
6. FDA Approves Viibryd to Treat Major Depressive Disorder
7. FDA Approves Head Lice Treatment for Children and Adults
8. FDA Approves Opioid Analgesic to Help Cancer Patients Manage Pain
9. VIDEO from Endo Pharmaceuticals Available on thenewsmarket.com: FDA Approves New Treatment for Low Testosterone
10. FDA Approves New Dosage Strength for INTELENCE®
11. U.S. FDA Approves Second Bayer Oral Contraceptive That Also Raises Folate Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation ... announced that it has received commitments from institutional ... million of the Company,s common stock in an ... health care fund. The Company entered ... to which the Company agreed to sell an ...
(Date:1/15/2014)... -- BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ... Ltd (NYSE: TEVA ) and its subsidiaries ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ... VSRNAs are of molecular size less than 10 bps, ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... RALEIGH, N.C., Feb. 17, 2011 BioDelivery Sciences International, ... enrollment of its Phase 3 trial assessing the efficacy ... moderate to severe chronic pain is on schedule, with ... (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) "We are very pleased ...
... Feb. 17, 2011 Reportlinker.com announces ... is available in its catalogue: ... - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones ... http://www.reportlinker.com/p0397051/Anti-Bacterials-Market-to-2016---Cephalosporins-Penicillins-Macrolides-and-Fluoroquinolones-to-Drive-the-Anti-Bacterials-Market.html ...
Cached Medicine Technology:BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule 2BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule 3Reportlinker Adds Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market 2Reportlinker Adds Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Fla., July 31 Sky Development Inc.,announces that ... of the first of two Class A medical ... Center at 2201 North University Drive,Pembroke Pines, Florida ... The medical/professional office complex, with smart building technology,and ...
... may represent an increased risk of developing cardiovascular disease, ... academic journal Atherosclerosis , has now led to ... , Atherosclerosis (hardening of the arteries) is an inflammatory ... are thickened and become less elastic. It can cause ...
... 31 Affiliated Computer Services,Inc. (NYSE: ACS ... $100,million, with UMass Memorial Health Care, Inc., a ... The contract will extend an existing six-year business,relationship., ... will provide a cost-effective,method of expanding UMass Memorial,s ...
... with the Most Cost-Effective 2-3 Year,Plan for Achieving ... HATBORO, Pa., July 31 InfoLogix, Inc.,(Nasdaq: ... mobility and,advanced wireless asset tracking solutions for the ... launched a new Strategic,Mobility Assessment Service for hospitals ...
... Miami Herald providing online readers with a fully-branded implementation of ... ... Miami, FL (PRWEB) July 31, 2008 -- HealthCare.com, Inc. ... today announced a partnership whereby The Miami Herald Media Company, ...
... Nutraceutical,International Corporation (Nasdaq: NUTR ) today reported results ... Net sales for the fiscal,2008 third quarter were $40.5 ... fiscal 2007. For the third quarter of fiscal 2008, ... share, compared to,net income of $2.9 million, or $0.25 ...
Cached Medicine News:Health News:50% Pre-Leased at Park Plaza Professional Center in Pembroke Pines 2Health News:New discovery may lead to immunization against cardiovascular disease 2Health News:ACS Signs Five-Year, $100 Million Deal to Provide Technology Services to UMass Memorial Health Care, Inc. 2Health News:ACS Signs Five-Year, $100 Million Deal to Provide Technology Services to UMass Memorial Health Care, Inc. 3Health News:InfoLogix Launches Strategic Mobility Assessment Service for Hospitals 2Health News:InfoLogix Launches Strategic Mobility Assessment Service for Hospitals 3Health News:HealthCare.com Adds The Miami Herald to its Care Provider Search™ Network 2Health News:HealthCare.com Adds The Miami Herald to its Care Provider Search™ Network 3Health News:Nutraceutical Reports Q3 Results 2Health News:Nutraceutical Reports Q3 Results 3Health News:Nutraceutical Reports Q3 Results 4Health News:Nutraceutical Reports Q3 Results 5Health News:Nutraceutical Reports Q3 Results 6
CDIs Chin Support Bandage is ideal for Submental Liposuction, Chin Implants and all other facial procedures requiring support. Adjustable Velcro® top and posterior band secures placement....
Four way compression with five contact closures...
Applies pressure on scalp to stretch it before surgery...
Facial Mask...
Medicine Products: